CRL·Charles River Laboratories International, Inc.

Charles River Laboratories International (CRL) is a global provider of essential services to the pharmaceutical and biotechnology industries, operating across research models and services, discovery and safety assessment, and manufacturing solutions. The company plays a critical role in supporting the drug development lifecycle, from early-stage research to manufacturing, within the Healthcare sector's Diagnostics & Research industry. In its most recent reported quarters, CRL demonstrated mixed performance against analyst expectations. For Q1 2026, the company reported an Earnings Per Share (EPS) of $2.06, exceeding the estimate of $1.94, and revenue of $995.83 million, surpassing the estimate of $987.26 million. This followed a Q4 2025 where EPS of $2.39 missed the estimate of $2.56, and revenue of $994.23 million slightly missed the estimate of $998.10 million. Prior to this, Q2 2025 saw a strong EPS beat of $3.12 against an estimate of $2.55, with revenue at $1.03 billion. The preceding quarter, Q1 2025, also featured an EPS beat of $2.34 versus an estimate of $2.07, with revenue at $984.17 million. Historically, CRL has shown a pattern of revenue growth, though EPS performance against estimates has been inconsistent, with beats in Q4 2024, Q1 2025, and Q2 2025, followed by a miss in Q4 2025. Recent news highlights CRL's position as a significant provider in the drug discovery and development services market, particularly within the expanding transgenic animals market, which is projected for substantial growth. Furthermore, a recent Memorandum of Understanding with Medipost to collaborate on Good Manufacturing Practice (GMP) compliant testing for cell therapies signals an expansion of CRL's service offerings in the biopharmaceutical testing sector, specifically targeting the growing cell therapy market. Looking ahead, investors will be watching for CRL's ability to leverage its strategic partnerships, such as the one with Medipost, to capture market share in specialized areas like cell therapy testing. Key will be the company's performance in upcoming quarters to see if it can maintain its revenue growth trajectory and achieve more consistent EPS beats against analyst estimates, particularly in light of the expanding transgenic animals market and its role in supporting biopharmaceutical production.